Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: week 52 results from Spirit-P1 and Spirit-P2 studies

Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: week 52 results from Spirit-P1 and Spirit-P2 studies

Abstract Background The efficacy and safety of ixekizumab (IXE) with and without continuous concomitant methotrexate (MTX), for up to 52 weeks of treatment, were evaluated in patients with active psoriatic arthritis (PsA). Methods Patients with active PsA who were biologic-naive (SPIRIT-P1) or had p...

Full description

Bibliographic Details
Main Authors: Bernard Combe, Tsen-Fang Tsai, J. Eugene Huffstutter, Aubrey Trevelin Sprabery, Chen-Yen Lin, So Young Park, Andris Kronbergs, Matthew M. Hufford, Peter Nash
Format: Article
Language:English
Published: BMC 2021-01-01
Series:Arthritis Research & Therapy
Subjects:
Psoriatic arthritis
Ixekizumab
cDMARDs
Methotrexate
Online Access:https://doi.org/10.1186/s13075-020-02388-5

Internet

https://doi.org/10.1186/s13075-020-02388-5

Similar Items